SCHEMBL376891

SCHEMBL376891

COC1(Cc2ccccc2F)CCN(c2ccc(C#N)cc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
TP53 P04637 1/20 0.45
CHRNA10 Q9GZZ6 1/20 0.40
CHRNA9 Q9UGM1 1/20 0.40
KCNH2 Q12809 1/20 0.39
MAPKAPK2 P49137 2/20 0.39
MCHR1 Q99705 2/20 0.39
KMT2A Q03164 3/20 0.38
BCL2L1 Q07817 2/20 0.37
BCL2 P10415 1/20 0.37
EP300 Q09472 1/20 0.37
MAPT P10636 1/20 0.36
DPP4 P27487 1/20 0.36
MEN1 O00255 2/20 0.36
POLB P06746 1/20 0.36
HTT P42858 1/20 0.35
AOC3 Q16853 1/20 0.35
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL376293 0.87 CHRNA10 (0.40) KDM4ETP53CHRNA10CHRNA9KCNH2
SCHEMBL376959 0.86 KDM4E (0.49) KDM4ETP53CHRNA10CHRNA9KCNH2
SCHEMBL376704 0.86 CHRNA10 (0.40) KDM4ETP53CHRNA10CHRNA9KCNH2
SCHEMBL2962385 0.84 KMT2A (0.38) KDM4ETP53KMT2ABCL2L1BCL2
SCHEMBL376939 0.84 MAPKAPK2 (0.45) KDM4ETP53CHRNA10CHRNA9KCNH2
SCHEMBL381688 0.83 KCNH2 (0.50) KDM4ETP53CHRNA10CHRNA9KCNH2
SCHEMBL13503798 0.81 ALDH1A1 (0.42) KDM4EKMT2ABCL2L1BCL2MAPT
SCHEMBL386110 0.81 F2 (0.47) KMT2ABCL2L1BCL2MAPTMEN1
SCHEMBL2965712 0.81 BCL2L1 (0.46) KDM4ETP53KMT2ABCL2L1BCL2
SCHEMBL376911 0.80 PARP14 (0.45) TP53CHRNA10CHRNA9KMT2ABCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765778-B1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2012-01-25 EP disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-7585858-B2 N-sulfonylcarboximidamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-09-08 US disclosed
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters ABBVIE INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BAD KDM4E 1408/4885TP53 30/4885CHRNA10 4259/4885
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters BAX, BCL2, BAD KDM4E 1408/4885TP53 30/4885CHRNA10 4259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.